Medicines Transparency Alliance: Options for MeTA Phase II Governance and Administration Arrangements Hosted by the World Bank

In the shorter term, there are two options for administration of a World Bank-hosted multi-donor trust fund (MDTF) for the Medicines Transparency Alliance (MeTA):  A recipient-executed MDTF, hosted in the Bank’s Health Anchor (HDNHE) for the bulk of funds, with a small “child trust fund” executed by the World to cover its costs of promoting… Read more




Evaluation of the Medicines Transparency Alliance Phase 1, 2008-2010

The Medicines Transparency Alliance (MeTA) was created in recognition of the key importance of access to medicines. These documents report on: Establishing a framework for MeTA in pilot countries; gaining government commitment and establishing sectoral and national committees. Delivering against the MeTA objectives in countries; progress towards data identification, disclosure, changes in practice and logframe… Read more




Aligning ACT Supply and Demand: Short and Long Term Options

HSRC REPORT: This paper considers the short and longer term options for aligning supply and demand of artemisin-based combination therapy (ACT) for Malaria. This is set on a background of increasing pressure for countries to change their anti-malaria drug policy to ACT (Artemisin-based Combination Therapies), by the World Health Organisation. However, despite the fact that… Read more




Independent Review of Medicines for Malaria Venture

HRC REPORT: This report reviews MMV’s(Medicine for Malaria Ventures) mission, governance structures, management and operations, factors contributing to its successes to date and challenges for the future. It also analyses the different public-private partnerships formed by MMV, looking at the benefits of partnerships between ‘academia, industry and the public sector’.  




Briefing Note on Advance Purchase Commitments

HSRC REPORT: This paper discusses the value-added of Advance Purchase Commitments, how they could be used alongside other incentives and investment approaches and the potential impact they might have on different types of product, stages of product development and types of firms, especially regarding health technologies in poor countries.It also highlights the different taxonomies used… Read more




Access to Medicines and Drug Regulation in Developing Countries: a Resource Guide for DFID

HSRC REPORT:This paper is an introduction to the key issues and debates in access to medicines (ATM) and drug regulation in developing countries. It outlines the current debates in ATM and regulation as well as providing details of the evidence base, including detailed references of studies and papers which have focused on specific issues and… Read more




Processes and Issues for Improving Access to Medicines: The evidence base for domestic production and greater access to medicines

HSRC REPORT: This study extrapolates empirical cost data from Sub-saharan African firms to consider the conditions under which domestic production of drugs in a facility in Sub-saharan Africa would be feasible and profitable as a business enterprise, while at the same time, able to promote better access to quality medicines, at a price more affordable… Read more




Access to Medicines in Under-served Markets

HSRC REPORT: An overview paper of seven new studies commissioned by the Access to Medicines team at the Department for International Development which focused on issues of current concern and debate in developing countries. The paper also explores issues related to international trade, intellectual property and drug registration requirements. It explores how these policy trends… Read more




Page 3 of 41234
css.php